Modified Nucleotides for mRNA Therapeutics: Pseudouridine, m1Ψ, and Beyond

Aug 15, 2025

As the field of mRNA therapeutics continues to expand—spanning vaccines, oncology, protein replacement, and gene editing—scientists are constantly optimizing their tools to improve safety, efficacy, and durability. One of the most impactful innovations in this space is the use of modified nucleotides, which play a central role in enhancing mRNA stability, reducing immunogenicity, and increasing translational efficiency.

At Areterna, we supply high-purity, research- and GMP-grade modified nucleotides designed to meet the evolving needs of both discovery and clinical-stage programs. In this post, we’ll explore the science and applications of several key modified nucleotides—starting with the most widely used: pseudouridine and N1-methylpseudouridine.

Why Modify Nucleotides?

Unmodified synthetic mRNA tends to activate innate immune responses through pattern recognition receptors like TLR7/8 and RIG-I. This triggers inflammation and can degrade the mRNA before it has a chance to produce therapeutic proteins. Modified nucleotides were developed to bypass these innate immune sensors while simultaneously boosting protein expression.

The result? mRNA that’s more stable, less immunogenic, and more potent.

Pseudouridine (Ψ): The Pioneer

Pseudouridine is the most abundant RNA modification found in nature. When substituted for uridine in synthetic mRNA, it:

  • Reduces innate immune recognition
  • Improves mRNA stability
  • Increases translational capacity

Pseudouridine was the foundational modification used in early mRNA vaccine trials and remains a go-to option for many academic and translational researchers.

N1-Methylpseudouridine (m1Ψ): The Gold Standard for mRNA Vaccines

N1-methylpseudouridine, or m1Ψ, is a next-generation uridine analog that offers even greater benefits than pseudouridine. It became widely adopted during the COVID-19 vaccine race and was used in the Pfizer-BioNTech and Moderna vaccines.

Key advantages of m1Ψ:

  • Significantly enhances protein production
  • Suppresses innate immune activation more effectively than Ψ
  • Improves pharmacokinetics and half-life of mRNA in vivo

Areterna offers high-purity m1Ψ suitable for in vitro transcription (IVT), supporting both research and scale-up needs.

What’s Beyond m1Ψ?

The field of mRNA engineering is far from static. Researchers are exploring a new generation of modified nucleotides to further refine and customize mRNA behavior.

Examples include:

  • 5-methylcytidine (m5C): Used alongside pseudouridine to reduce immune sensing
  • 2-thiouridine (s2U): Offers potential immune modulation
  • N6-methyladenosine (m6A): Involved in mRNA localization and turnover
  • Base analogs for targeted degradation kinetics or tissue-specific translation control

As therapeutic mRNA applications diversify, the need for tailored nucleotide chemistries will only grow.

Areterna’s Role in Supporting Innovation

At Areterna, we recognize that modified nucleotides are not just reagents—they’re critical building blocks in tomorrow’s therapeutics. That’s why we’re committed to providing:

  • Ultra-pure nucleotides for high-efficiency IVT
  • Cost-effective NTPs for research and beyond
  • Scalable production for research through GMP pipelines
  • Custom synthesis for novel base modifications

Whether you’re optimizing your IVT protocol, troubleshooting low expression yields, or preparing for IND-enabling studies, our team is here to support your raw material needs with scientific and operational expertise.

Let’s build the future of mRNA together. Explore our full range of modified nucleotides here or contact our team for technical guidance and bulk inquiries.